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Cisplatin is a widely used antineoplastic agent that has DNA as the main target, though cellular resistance hampers its therapeutic
efficacy. An emerging hallmark of cancer cells is their altered metabolism, characterized by increased glycolysis even under aerobic
conditions, with increased lactate production (known as the Warburg effect). Although this altered metabolism often results in
increased resistance to chemotherapy, it also provides an opportunity for targeted therapeutic intervention. It has been
suggested that cisplatin cytotoxicity can be affected by tumor metabolism, though with varying effects. We therefore sought to
better characterize how lactate affects cisplatin sensitivity in the simplified Saccharomyces cerevisiae model. We show that lactate
renders yeast cells resistant to cisplatin, independently of growth rate or respiration ability. We further show that histone
acetylation is not affected, but histone phosphorylation is decreased in lactate-containing media. Finally, we show that Rad4p,
essential for nucleotide excision repair, is required for the observed phenotype and thus likely underlies the mechanism
responsible for lactate-mediated resistance to cisplatin. Overall, understanding how lactate modulates cisplatin sensitivity will
aid in the development of new strategies to overcome drug resistance.
1. Introduction
Cisplatin is a platinum-based drug used in the treatment of
various solid neoplasms, such as head and neck, lung, colo-
rectal, and ovarian cancers [1]. This chemotherapeutic drug
is administered either alone or combined with other drugs
[2] and, depending on the dose, can induce irreparable
DNA damage leading to cell cycle arrest or cell death, usually
by apoptosis [3]. Despite its effectiveness, cellular resistance
still occurs, either intrinsic or acquired [4]. Resistance is a
multifactorial problem, and the most studied mechanisms
range from defects in mismatch repair, aneuploidy, increased
cisplatin detoxification, and failure to undergo apoptosis [5,
6]. More recently, increased attention has been given to the
metabolism of tumor cells and how it affects chemoresis-
tance. Unlike normal cells, cancer cells predominantly pres-
ent a glycolytic profile even in the presence of oxygen,
associated with high uptake of glucose and lactic acid pro-
duction [7, 8], known as the Warburg effect or “aerobic gly-
colysis” [9, 10]. It is postulated that this type of metabolism
can lead to a faster production of ATP and accumulation of
bioprecursors to fit cellular demand [11] but may also influ-
ence the response of cancer cells to therapy [12]. Indeed, a
high lactate concentration in tumors is associated with bad
prognosis [13]. However, the connection between metabo-
lism and response to therapy is not always clear-cut. Indeed,
tumors are inherently heterogeneous and can include both
oxidative and glycolytic cells, depending, among other fac-
tors, on vascularization and oxygen availability (reviewed in
[14, 15]). A “Reverse Warburg Effect” has also been pro-
posed, whereby cells in the tumor microenvironment are
induced to provide metabolites to fuel cancer cells. For
instance, lactate released by glycolytic cells can be recaptured
by oxidative cancer cells to use as fuel, but also function as a
signaling molecule affecting chemosensitivity (reviewed in
[16, 17]) [18]. Nonetheless, results are often contradictory.
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In particular, it has been reported that treatment with cis-
platin can lead to inhibition of glycolysis [19], and that inhi-
bition of glucose metabolism can increase sensitivity to the
drug, often through increased ROS levels [20, 21]. Cisplatin
treatment also decreases mitochondrial respiration in
in vitro cultures of HT-29, HCT116, HepG2, and MDA-
MB-231, followed by a decrease in glycolysis [22]. However,
while some cisplatin-resistant cell lines display higher rates
of glycolysis [23–26], others have increased oxidative metab-
olism [27, 28]. This indicates that the relation between
metabolism and cisplatin sensitivity depends on the type of
tumor or cell line under study, as well as experimental condi-
tions. Since we have previously shown that cisplatin induces
an active, but mitochondrial-independent cell death process
in Saccharomyces cerevisiae [29], we took advantage of this
simpler model to clarify the role of lactate in cisplatin-
induced cell death.
2. Materials and Methods
2.1. Growth Conditions and Treatments. The Saccharomyces
cerevisiae strains used in the experimental procedures and
respective genotypes are listed in Table 1. Cells were grown
overnight, at 30°C and 200 rpm, in synthetic complete (SC)
medium (5.0 g/L ammonium sulphate ((NH4)2SO4), 1.4 g/L
dropout mix, 1.7 g/L yeast nitrogen base w/o amino acids
and w/o ammonium sulphate ((NH4)2SO4), and 2% glucose
(w/v)). After overnight growth, cells were collected at OD
(A640) 0.5-0.7 and transferred to new SC medium containing
2% of the indicated carbon source (glucose or lactate). The
pH of all media was adjusted to 5.0-5.5. Cisplatin (CDDP;
Sigma) was added afterwards to a final concentration of
600μg/mL or 450μg/mL. Cisplatin was stored in aliquots in
the dark and resuspended in DMSO immediately prior to
use. However, although the phenotype in relation to control
was consistent, some variability in cytotoxicity between inde-
pendent experiments and different cisplatin lots was unavoid-
able. Methyl methanesulfonate (MMS; Fluka) was used as a
positive control at a final concentration of 0.1%. α-mating fac-
tor was used at a final concentration of 1mg/mL in glucose-
containing media, to decrease the specific growth rate by
arresting cells at the G1 cell cycle phase.
2.2. Viability Assays. For semiquantitative viability assays,
5μL of cell suspensions and tenfold serial dilutions (10-1 to
10-4) were spotted on YPD plates (1% (w/v) yeast extract,
2% (w/v) peptone, 2% (w/v) glucose, and 2% (w/v) agar).
After 2 days of incubation at 30°C, all plates were photo-
graphed using Chemidoc XRS (BioRad) and analyzed by
Quantity One (BioRad).
For quantitative viability assays, 40μL of cell suspensions
were spotted on YPD plates. After 2 days of incubation at
30°C, colony-forming units (c.f.u.) were counted and nor-
malized to the OD (A640) values. The percentage of cell via-
bility was then calculated in relation to T0 (considered as
100% of cell viability). Results are expressed as mean ±
standard deviation. Each experiment was performed at least
3 times. GraphPad Prism 5 was used for statistical analysis.
2.3. Western Blot. Total cellular extracts were separated in a
12.5% polyacrylamide gel (SDS-PAGE). Following electro-
phoresis, proteins were transferred onto a nitrocellulose mem-
brane at 60mA for 90 minutes, using a semidry system
(TE77X, Hoefer, USA). Membranes were blocked for 1h in
5% nonfat dry milk and diluted in PBS-T (PBS containing
0.05% (v/v) Tween-20), under low agitation. Subsequently,
for phosphorylatedH2A, H3 acetylation, and Pgk1p detection,
membranes were incubated overnight at 4°C with the primary
polyclonal antibodies anti-γH2AX (1 : 5000, Abcam), anti-
acetyl-Histone H3 (Lys9) (1 : 5000, Millipore), or anti-PGK1
(1 : 5000, Molecular Probes), respectively. The next day, mem-
branes were washed 3 × 5 minutes with PBS-T, followed by a
1h room temperature incubation with the secondary anti-
bodies anti-rabbit (for γH2AX and acetyl-Histone H3) or
anti-mouse (for Pgk1p) from Jackson Laboratories. Chemilu-
minescence detection was performed using the Immobilon
ECL detection system (Millipore-Merck) and a Chemi-
DOC XRS system (BioRad) or X-ray ortho CP-G films in
an X-ray film processor (Curix 60, Agfa Healthcare).
3. Results and Discussion
3.1. Lactate Protects S. cerevisiae Cells from Cisplatin-Induced
Cell Death. To uncover the influence of lactate on cisplatin
sensitivity, we assessed the viability of BY4741 cells exposed
to cisplatin in medium containing glucose or lactate for up
to 180min. As a control, we also assessed viability of cells
exposed to methyl methanesulfonate (MMS), a DNA alkylat-
ing agent [30]. As seen in Figure 1, lactate increased viability
of cells exposed to cisplatin, but did not seemingly affect via-
bility of cells exposed to MMS. This indicates that lactate spe-
cifically protects cells from cisplatin exposure, which may be
contingent on the type of DNA damage or the pathways
involved in its repair.
Indeed, MMS is a DNA-alkylating agent that causes
alterations in guanine and adenine residues, resulting in
base mispairing, and is predominantly repaired by the base
excision repair (BER) pathway and DNA alkyltransferase
[31]. In contrast, intrastrand crosslinks caused by cisplatin
Table 1: S. cerevisiae strains used in this work.
Strain Genotype Reference
BY4741 MATa his3Δ1; leu2Δ0; met15Δ0; ura3Δ0 [42]
rho0 BY4741 rho0 A. Rego
bar1Δ BY4741 bar1Δ::KanMX4 Euroscarf (Germany)
rad4Δ BY4741 rad4Δ::URA3 This study
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are mainly repaired by the nucleotide excision repair
(NER) pathway [32].
Another contributing factor that may influence resistance
to cisplatin could be the slower growth rate of yeast cells.
Indeed, cells grow slower in lactate-containing media, which
could result in additional time to repair DNA damage
induced by cisplatin and underlie the observed increased
resistance. To address this hypothesis, we assessed whether
decreasing the growth rate in glucose-containing media
affected cisplatin resistance. For this purpose, BY4741 bar1Δ
cells were grown overnight in glucose-containing medium,
pretreated with α-factor and exposed to cisplatin for
180min (the BAR1 deletion was used to decrease α-factor
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Figure 1: Effect of lactate on cisplatin and MMS sensitivity. Wild-type BY4741 cells were grown to early exponential phase in SC-glucose
medium (pH 5.5). Cells were washed and exposed to 600μg/mL cisplatin or 0.1% MMS in SC medium containing glucose or lactate for up
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Figure 2: Effect of the growth rate on cisplatin sensitivity. bar1Δ cells were grown to early exponential phase in SC-glucose medium (pH5.5).
Cells were pretreated with α-mating factor for 3 hours, exposed to cisplatin for 180 minutes, and plated on YPD. (a) Calculation of the specific
growth rate (h-1) and statistical analysis by Prism 5 (one-way ANOVA and Tukey test; ∗∗∗P < 0:0001). (b) Cell viability was estimated by
semiquantitative spot assay over time. (c) Since no clear differences were observed by spot assay in (b), cell viability was quantified by
c.f.u. counts in relation to time 0. Mean ± SD from 3 independent experiments is shown. Differences were not statistically significant.
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specific growth rate over the 3 h of cisplatin exposure to a
level comparable or even lower to that of cells grown in
lactate-containing media, consistent with a cell cycle arrest
during this period. However, similar viability was observed
in cells exposed to cisplatin in the presence or absence of α-
factor (with a tendency for lower viability in the presence of
α-factor that was not significant). This indicates that it is
not the decreased growth rate but the presence of lactate that
increases cisplatin resistance.
Apart from the decreased growth rate, cells grown in lac-
tate media also display a different metabolic status, i.e., cells
switch to a respiratory metabolism. As referred above, several
studies report a connection between cisplatin and oxidative
metabolism, though the mechanism and effects are complex.
On one hand, studies show that exposure to cisplatin can itself
lead to increased oxidative phosphorylation, suggesting that
inhibition of tumor glycolytic metabolism could underlie
decreased proliferation in response to the drug [19, 33]. On
the other hand, although cisplatin-resistant and cisplatin-
sensitive cells tend to display different energy metabolism,
opposing effects are often found (reviewed in [12]). For
instance, cisplatin-resistant ovarian and cervical cancer cells
had higher rates of glycolysis whereas cisplatin-resistant lung
cancer cells displayed increased oxidative phosphorylation in
comparison with their cisplatin-sensitive counterparts [24–
28]. To assess whether respiration affected cisplatin resistance
in yeast cells, we determined whether the protective effect of
lactate was still observed in the respiratory-deficient rho0
strain, which lacks mitochondrial DNA.
As seen in Figure 3, rho0 cells were still more resistant to
cisplatin in lactate-containing media, as observed in wild-
type BY4741 cells. This indicates that it is not respiration
per se that increases cisplatin resistance when shifting from
fermentative to nonfermentative carbon sources during cis-
platin exposure. These results therefore suggest that it is the
lactate signaling role, in the modulation of processes other
from respiration, that protects cells from cisplatin-induced
death. Indeed, lactate is increasingly regarded as not just
the end result of the Warburg effect but as an important
molecule in driving carcinogenesis [7–10] (reviewed in
[34]). While some of its effects are specific to multicellular
organisms (such as increased angiogenesis), others occur
at the cellular level, such as the effects of lactate on chroma-
tin and transcription.
3.2. Cisplatin-Induced DNADamage Response Is Decreased in
Lactate-Containing Medium. It has previously been
described that lactate is a weak histone deacetylase (HDAC)
inhibitor in HCT116 cells [35], resulting in increased levels
of histone acetylation, associated with more relaxed chroma-
tin. Histone acetylation has also been implicated in the regu-
lation of the DNA damage response (DDR) in mammalian
BY4741
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Figure 3: Effect of lactate on cisplatin-induced cell death of respiratory-deficient cells. Wild-type BY4741 and respiratory-deficient rho0 cells
were grown to early exponential phase in SC-glucose medium (pH 5.5). Cells were washed and exposed to 600μg/mL cisplatin in SC medium
containing glucose or lactate for up to 180 minutes. Cell viability was assessed by semiquantitative spot assay on YPD plates. A representative
image from 3 independent experiments is shown.
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Figure 4: Effect of lactate on H3 acetylation during cisplatin treatment. Wild-type BY4741 cells were grown to early exponential phase in SC-
glucose medium (pH5.5). Cells were washed and exposed to 600μg/mL cisplatin in SC medium containing glucose or lactate for up to 180
minutes. H3 acetylation levels were assessed by Western blot. Pgk1p levels were used as a loading control. A representative image from 3
independent experiments is shown.
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Figure 5: Effect of lactate on H2A phosphorylation during cisplatin treatment. Wild-type BY4741 cells were grown to early exponential phase
in SC-glucose medium (pH5.5). Cells were washed and exposed to 600μg/mL cisplatin in SC medium containing glucose or lactate for up to
180 minutes. H2A phosphorylation levels were assessed by Western blot. Pgk1p levels were used as a loading control. A representative image
from 2 independent experiments is shown.
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Figure 6: Effect of RAD4 deletion on lactate-mediated resistance to cisplatin. Wild-type BY4741 and rad4Δ cells were grown to early
exponential phase in SC-glucose medium (pH5.5). Cells were washed and exposed to cisplatin in SC medium containing glucose or
lactate for up to 180 minutes. (a) Cell viability was assessed by semiquantitative spot assay, (b) colony forming units (c.f.u.) of cells
exposed to 450μg/mL cisplatin for 120 minutes for rad4Δ and 180 minutes for wild-type BY4741, and (c) c.f.u. of cells exposed to
600μg/mL cisplatin for 120 minutes for rad4Δ and 180 minutes for wild-type BY4741. In (b) and (c), cell viability was determined by
standard dilution plate counts and expressed as a percentage of c.f.u. on YPD plates in relation to time 0. Statistical analysis by Prism 5
(two-way ANOVA and Sidak’s multiple comparisons test); ∗∗∗∗P < 0:0001. Values represent mean ± SD of four independent experiments.
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cells, and lactate has been shown to increase chromatin
accessibility and DNA repair in cervical cancer cells [36].
We therefore sought to determine whether lactate could alter
the levels of histone acetylation in yeast cells. For this pur-
pose, we assessed the levels of H3 acetylation in extracts of
cells exposed to cisplatin in glucose or lactate-containing
media, by Western blot (Figure 4).
We could not detect any increase in H3 acetylation levels
under our experimental conditions, suggesting that the
observed cisplatin resistance in the presence of lactate is not
related with increased histone acetylation. Though lactate
did not seem to act by epigenetic regulation of chromatin
in this case, it could still affect DDR through other mecha-
nisms. One particularly well-known and early event that
occurs after DNA damage is the phosphorylation of histone
H2A or H2AX, in higher eukaryotes. In yeast, it is well estab-
lished that H2A is phosphorylated in response to DNA dam-
age, as we have previously shown in response to cisplatin
[37]. We therefore assessed the levels of H2A phosphoryla-
tion in extracts of cells exposed to cisplatin in glucose or
lactate-containing media, by Western blot (Figure 5).
We observed that the levels of phospho-H2A were much
lower in the latter, suggestive of lower levels of damaged
DNA or inhibition of the DNA damage response. However,
decreased DDR should not result in increased viability; quite
on the contrary, it usually results in increased sensitivity to
DNA damage [38, 39]. It is, therefore, more likely that expo-
sure to cisplatin in the presence of lactate results in
decreased initial DNA damage or increased DNA repair in
yeast cells.
3.3. Nucleotide Excision Repair Is Required for Lactate-
Induced Cisplatin Resistance. Taken together, the previous
results indicate that the presence of lactate results in
decreased initial cisplatin DNA damage or increased damage
repair, which is difficult to distinguish biochemically. We
therefore sought to determine whether DNA repair was
required for the observed phenotype. As mentioned above,
the DNA damage induced by platinum drugs is mainly
repaired by the NER pathway [40], and it is well established
that Rad4p is indispensable for NER activity [41]. We there-
fore deleted the RAD4 gene in BY4741 cells and assessed
whether lactate still rescued rad4Δ cells from cisplatin-
induced cell death (Figure 6).
Because rad4Δ cells are highly sensitive to cisplatin, a
lower concentration of cisplatin was also used. For both con-
centrations, it was possible to observe that lactate did not
greatly increase the resistance of rad4Δ cells to cisplatin
(Figure 6). Indeed, the percentage of surviving wild-type cells
was significantly greater in lactate media than in glucose
media after 180min of cisplatin exposure (panels b and c).
In contrast, only a minor increase was observed in the
rad4Δ strain (measured at the 120min time point since, after
180min, there were virtually no viable cells exposed to either
concentration of cisplatin). Taken together, though a contri-
bution from another mechanism cannot be excluded, these
results indicate that the NER pathway plays an important
role in the protection from cisplatin-induced cell death
imparted by lactate.
4. Conclusions
In this work, we show that lactate specifically increases resis-
tance to cisplatin, independently of the cellular growth rate
and respiratory capacity. This process was associated with
decreased DNA damage, probably through increased NER,
as Rad4p was required for the observed resistance. It is well
established that repair-deficient tumor cells are particularly
sensitive to cisplatin, which has been attributed to a
decreased capacity to repair the DNA lesions. Our work sug-
gests that NER deficiency may further contribute to chemo-
therapy efficacy by attenuating acquired resistance of tumor
cells in a lactate-containing microenvironment, which war-
rants further investigation.
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